Remegen Co., Ltd.

This study tested a new drug called RC88 in 43 women with ovarian, fallopian tube, or peritoneal cancer that stopped responding to platinum chemotherapy. The goal was to see if RC88 could shrink tumors and how safe it was. Participants had already tried at least three other treat…

This study tested an experimental drug called RC108 in 29 adults with advanced digestive system cancers that have a specific marker (c-Met). The goal was to see if the drug could shrink tumors or stop them from growing. Participants received the drug and were monitored for side e…

This study tested a new drug called telitacicept in 381 adults with active primary Sjogren's syndrome, an autoimmune disease causing dry eyes and mouth. Participants received either the drug or a placebo as a shot under the skin. The main goal was to see if the drug reduces overa…

This study tested an experimental drug called RC88 in 198 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to see if the drug is safe and to find the best dose. Researchers also looked for early signs that the drug might shrink tu…

This early-stage study tested a drug called telitacicept in 16 children with lupus. The main goal was to see how the drug moves through the body and to check for early signs of effectiveness. All children were already on standard lupus treatments.

This early-phase study tested an experimental drug called RC108-ADC in 67 adults with advanced solid tumors that have a specific protein (c-Met). The main goals were to check safety, find the best dose, and see if the drug shrinks tumors. Participants received the drug by injecti…

This study provided continued access to the experimental drug RC88 for patients with advanced solid tumors who had already participated in earlier research. The main goal was to further assess the safety and side effects of RC88 treatment. Researchers also measured how well the d…